证券研究报告 | 公司点评报告 2025 年 08 月 26 日 天坛生物（600161.SH） 收入维持稳定增长，重八放量在即 消费品/生物医药 公司发布 2025 年中报。2025H1 实现收入 31.10 亿元，归母净利润 6.33 亿元， 扣非归母净利润 6.18 亿元，同比分别增长 9.47%，-12.88%，-14.54%。其中 2025Q2 实现收入 17.93 亿，归母净利润 3.88 亿，扣非归母净利润 3.79 亿，同 比分别增长 10.7%，-5.13%，-7.53%。 ❑ 风险提示：竞争加剧、新品推广不及预期、采浆不及预期等。 财务数据与估值 | 会计年度 | 2023 | 2024 | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入(百万元) | 5180 | 6032 | 7238 | 7962 | 8758 | | 同比增长 | 22% | 16% | 20% | 10% | 10% | | 营业利润(百万元) | 1805 | 2558 | 2634 | 2920 | 3240 | | ...

Core Viewpoint - The company has made significant progress in its operations, including the transfer of equity stakes, approval for new facilities, and advancements in clinical trials and smart factory construction. Group 1: Financial and Shareholder Information - The company plans to distribute a cash dividend of 1.50 yuan per 10 shares to all shareholders, based on a total of 504,248,738 shares [1] - There has been no change in the controlling shareholder or actual controller during the reporting period [1] Group 2: Major Corporate Actions - The company has approved the public transfer of 80% equity in Jiangxi Boya Xinha Pharmaceutical Co., Ltd., with a revised listing price of 158.1655 million yuan [3][4] - The company received approval to establish a single plasma collection station in Dalat Qi, Inner Mongolia [5] - The company obtained clinical trial approval for subcutaneous immunoglobulin and a supplementary drug application for intravenous immunoglobulin [6] Group 3: Operational Developments - The construction of the blood product smart factory is progressing well, with the main structure completed and various installations underway [6] - The company aims to set high standards for the smart factory project, positioning it as a benchmark in the biopharmaceutical industry [6] Group 4: Shareholder Actions - The controlling shareholder, China Resources Pharmaceutical Holdings Co., Ltd., has completed a share buyback plan, acquiring a total of 6,050,900 shares, representing 1.2% of the total share capital [7][8]

证券代码：300294 证券简称：博雅生物 公告编号：2025-058 华润博雅生物制药集团股份有限公司 关于 2025 年半年度利润分配预案的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 重要提示： 全体股东每 10 股派发现金红利 1.50 元（含税），送红股 0 股（含税），以资本 公积金向全体股东每 10 股转增 0 股。 在实施权益分派的股权登记日前，如享有利润分配权的股份总额发生变动， 则以实施分配方案时股权登记日的享有利润分配权的股份总额为基数，按照分配 比例不变的原则对分配总额进行调整。 （二）公司董事会审议情况 对、0票弃权的表决结果，审议通过《关于公司2025年半年度利润分配预案的议 案》，并同意将该议案提交公司2025年第一次临时股东大会审议，经批准后实施。 （三）公司监事会审议情况 根据中国证券监督管理委员会《上市公司监管指引第 3 号——上市公司现金 分红》及《公司章程》等规定，为充分考虑对投资者的回报，结合公司 2025 年 半年度实际生产经营情况及未来发展前景，华润博雅生物制药集团股份有限公司 （以下简称公司）于 2025 年 ...

8月22日，派斯双林生物制药股份有限公司（以下简称"派林生物（000403）"）发布2025年半年度报 告。尽管受子公司产能调整影响，公司上半年营收和净利润同比有所下滑。报告显示，今年上半年，派 林生物实现营业收入9.86亿元，同比下降13.18%；归属于上市公司股东的净利润2.36亿元，同比下降 27.89%；归属于上市公司股东的扣除非经常性损益的净利润2.15亿元，同比下降27.63%。 根据此前公司控股股东胜帮英豪与中国生物技术股份有限公司（简称"中国生物"）签署的《收购框架协 议》，正式交易文件最晚于9月10日发布。若交易完成，公司控制权将迎来重大变更，有望借助央企资 源实现战略升级。作为血液制品行业第一梯队企业，派林生物在行业集中度提升的背景下，正通过产能 优化与资本运作双轮驱动，巩固行业地位。 业绩短期调整筑根基 产能释放待下半年发力 派林生物主营业务为血液制品的研究、开发、生产和销售，血液制品属于生物制品行业的细分行业，主 要以健康人血浆为原料，采用生物学工艺或分离纯化技术制备的生物活性制剂，在医疗抢救及某些特定 疾病预防和治疗上，血液制品有着其他药品不可替代的重要作用，属于不可或缺的国家重要战 ...

上证报中国证券网讯 8月21日，天坛生物披露2025年半年度报告。上半年，公司实现营收31.10亿元，同比增长9.47%；实现归母净利润6.33亿元，同比下降12.88%。2025年第二季度实现营 报告显示，公司单采血浆站数量及采浆规模持续保持国内领先地位。截至目前，公司下属单采血浆站分布于全国16个省/自治区，单采血浆站总数达107家，其中在营单采血浆站数量达85家。上 创新研发方面，上半年，公司多个在研新产品取得阶段性突破。成都蓉生第四代层析工艺10%浓度静注人免疫球蛋白（规格：2.5g/瓶，10%，25ml）获得《药品补充申请批准通知书》；已提交 上半年，公司积极推动工程项目和信息化建设，加速智能化升级与产业协同发展，有力促进生产及管理质效提升。其中，成都蓉生重组因子车间项目完成竣工验收，注射用重组人凝血因子Ⅷ生产 国际业务方面，上半年，公司积极落实国际化战略布局，持续推进国际市场开发和注册准备工作，开展多个目标市场的产品注册资料编制、申报流程启动工作。同时，实现静注人免疫球蛋白（p 报告显示，公司下辖七家血液制品生产企业，拥有人血白蛋白、人免疫球蛋白、人凝血因子等三大类及重组凝血因子产品、15个品种、 ...

8月21日消息 "国家队"国药系大动作，承诺5年内整合天坛生物与派林生物，我国血液制品行业竞争格局将被 彻底改写！ 21日晚间，中国生物收购派林集团一事迎来最新进展。天坛生物公告称，公司收到实际控制人国药集团及控股 股东中国生物出具的承诺函，因中国生物收购派林生物21.03%股份导致与公司新增同业竞争，承诺在五年内通 过包括资产置换、资产出售、资产注入、设立合资企业等方式解决同业竞争问题。同时承诺不新增与天坛生物 主营业务构成竞争的业务，并公平对待下属控股企业。该承诺函自中国生物取得派林生物控制权之日起生效。 随后派林生物收到控股股东中国生物通知，中国生物与派林生物控股股东共青城胜帮英豪投资合伙企业（有限 合伙）（"胜帮英豪"）达成合作意向并签署《收购框架协议》，约定由中国生物或其指定子公司以现金方式协 议收购胜帮英豪持有的全部21.03%派林生物股份，以取得派林生物的控制权。 值得注意的是，中国生物旗下的天坛生物与派林生物的业务重合度极高，二者均以血液制品的研究、开发、生 产和销售为主。 8月4日，天坛生物发布公告称，为避免同业竞争，公司拟放弃收购派林生物商业机会，由天坛生物控股股东中 国生物技术股份有限公 ...

Core Viewpoint - The ongoing dispute between Luckin Coffee's chairman, Li Hui, and former chairman of Taibang Biologic, Zhou Fan, centers around the ownership of shares following the privatization of Taibang Biologic, with allegations of misleading investors and harming shareholder interests [2][5][11]. Group 1: Shareholder Dispute - Zhou Fan accuses Li Hui of unilaterally canceling the original management team's co-investment shares and redistributing them after the privatization of Taibang Biologic [2][3]. - Zhou Fan holds approximately 534,010 shares of Taibang Biologic, representing about 13.77% of the company, valued at over $656 million (approximately 4.6 billion RMB) based on a $4.76 billion valuation during privatization [4][6]. - The conflict escalates as both parties assert differing claims regarding the ownership of Zhou Fan's shares, with Taibang Biologic's management stating that Zhou is merely exercising voting rights on behalf of the platform [5][12]. Group 2: Company Background and Investment Strategy - Taibang Biologic, previously a publicly listed company, specializes in blood products and has been undervalued in the market [16][20]. - The investment strategy of Dazhong Capital, which includes high equity stakes and active involvement in management, is exemplified by its handling of both Luckin Coffee and Taibang Biologic [10][19]. - Dazhong Capital's approach contrasts with typical private equity firms, as it often seeks to gain control during governance crises, as seen in the cases of both companies [19][20]. Group 3: Market Context and Implications - The public conflict between partners in a private equity firm is unusual and suggests that internal resolutions have failed, potentially impacting the stability and long-term commitment of the management team [11][12]. - The management team at Taibang Biologic is currently in a precarious position, with the new management having already made decisions regarding share distribution, raising legal and regulatory concerns [12][20]. - The situation reflects broader implications for investor confidence and governance practices within the private equity sector, particularly in the context of management buyouts and share distribution disputes [11][20].

Investment Rating - The industry investment rating is "Outperform" [2] Core Insights - The report highlights the issuance of the "Implementation Opinions on Promoting the Innovation and Development of Brain-Machine Interface Industry" by the Ministry of Industry and Information Technology and six other departments, which increases certainty in the related industry [5][14] - The pharmaceutical and biotechnology sector has shown a 3.08% increase this week, outperforming the CSI 300 index by 0.7 percentage points, ranking 10th among 31 sub-industries [20][21] - The report indicates that the brain-machine interface technology is in a period of accelerated transformation, with domestic companies expected to gradually achieve commercialization, leading to rapid market expansion [6][17] Summary by Sections Industry Overview - The closing index for the industry is 9029.09, with a 52-week high of 9029.09 and a low of 6070.89 [2] Weekly Performance - The medical research outsourcing sector had the highest increase this week at 7.77%, followed by the hospital sector at 5.59% and medical consumables at 4.47% [7][21] - The report notes a significant divergence in performance among sub-sectors, with offline pharmacies experiencing the largest decline at 1.82% [7][21] Beneficiary Stocks - Beneficiary stocks in the innovative drug sector include companies such as Innovent Biologics, Kintor Pharmaceutical, and BeiGene for H-shares, and Zai Lab, Eucure Biopharma, and others for A-shares [8] - In the medical device and consumables sector, companies like Mindray Medical, Weigao Group, and others are highlighted as beneficiaries [8] Sub-sector Analysis - The report emphasizes that the innovative drug sector is expected to continue performing well due to overseas business development expectations and supportive policy documents [26] - The medical device sector is projected to benefit from policies promoting the replacement of old equipment, with significant growth expected in the second quarter of 2025 [27][28] - The IVD sector is anticipated to see marginal improvements due to optimized procurement policies, with AI-assisted diagnostics being a promising direction [31][32] Market Trends - The report indicates that the overall trend for the medical device industry is positive, driven by innovation, mergers, and internationalization, with leading Chinese companies expected to grow into global leaders [28] - The report also notes that the traditional Chinese medicine sector is expected to see a turning point as inventory clears and procurement policies are implemented [40]

Investment Rating - The report does not explicitly state an investment rating for the industry, but it indicates a positive trend in the pharmaceutical and biotechnology sector with a weekly increase of 3.08% [3][8]. Core Insights - The pharmaceutical and biotechnology sector outperformed the Wind All A index and the CSI 300 index during the week of August 11 to August 15, with notable gains in medical research outsourcing (7.77%), hospitals (5.59%), and medical consumables (4.47%) [3][8]. - The upcoming launch of the commercial insurance innovative drug directory is expected to activate the domestic high-end payment market for innovative drugs, with 121 drug names passing preliminary review [3][8]. - The World Conference on Lung Cancer (WCLC) will take place from September 6 to 9, showcasing significant research advancements in lung cancer, with domestic research playing an increasingly important role [3][8]. Market Weekly Review - The pharmaceutical and biotechnology sector rose by 3.08%, outperforming the Wind All A index (2.95%) and the CSI 300 index (2.37%) [3][8]. - Medical research outsourcing, hospitals, and medical consumables led the sector's gains, while offline pharmacies, blood products, and medical circulation experienced declines [3][8]. - Notable individual stock performances included Sino Medical (69.1%), Innovation Medical (51.5%), and Guangsheng Tang (40.7%) for gains, while *ST Suwu (-16.8%), ST Sansheng (-15.2%), and Nanhua Biological (-14.2%) faced significant losses [3][11]. Industry News and Key Company Announcements - The National Medical Insurance Administration announced the preliminary review of the 2025 National Basic Medical Insurance drug directory and the commercial insurance innovative drug directory [3][13]. - Novo Nordisk received accelerated FDA approval for its therapy Wegovy for treating non-alcoholic steatohepatitis (NASH) [3][13]. - Yunnan Baiyao approved a full acquisition of An Guo Shi Ju Yao Tang Pharmaceutical Co., Ltd. for 660 million RMB to enhance its traditional Chinese medicine business [3][15]. - Insmed's DPP1 inhibitor Brensocatib received FDA approval for treating non-cystic fibrosis bronchiectasis [3][14].

Company Overview - Shanghai Raist Blood Products Co., Ltd. was established in 1988 and listed on the Shenzhen Stock Exchange in 2008. In December 2023, Haier Group signed a strategic cooperation and share purchase agreement with Kilibof, acquiring 20% of the company’s shares through its subsidiary, Haiyingkang. The transaction was completed in June 2024, resulting in a change of controlling shareholder to Haiyingkang and actual controller to Haier Group [2][3]. Industry Situation - The blood products industry is a sub-sector of the biopharmaceutical industry, characterized by high technical barriers and strict regulatory requirements. Since 2001, no new blood product manufacturing enterprises have been approved in China, with fewer than 30 companies currently operating [3]. - In 2024, there were over 300 plasma collection stations in China, with a total plasma collection exceeding 13,000 tons, showing significant growth compared to 2023, although there remains a gap between supply and actual demand [3]. - Human albumin is the most significant product in terms of domestic sales, with a high proportion of imports. Imported human albumin is currently the only permitted human-derived blood product in China [3]. Company Goodwill - The company's goodwill primarily arises from the acquisition of other stable and well-performing enterprises in the same industry. The company conducts annual impairment testing of goodwill in compliance with regulatory requirements [4]. Sales and Market Dynamics - Domestic sales of human albumin have slightly slowed due to medical insurance policies and supply-demand dynamics. However, there remains a rigid demand for human albumin, which is used in various medical conditions [5]. - The blood products industry currently has some inventory among companies and distributors, with production and inspection cycles being relatively long [6]. - Prices of blood products have been affected by policy factors and supply-demand relationships, leading to some price reductions since the second half of last year [7]. Innovation and R&D - The company is advancing its "plasma expansion" and "plasma reduction" strategies, focusing on safety, quality, and efficiency, while increasing investment in basic research, clinical translation, and industrial upgrades [8]. - The company is conducting clinical research on SR604 injection, which is in Phase IIb trials. This product aims to prevent and treat hemophilia A and B, as well as factor VII deficiency [8][9]. Conclusion - The report highlights the strategic developments, market conditions, and innovation efforts of Shanghai Raist Blood Products Co., Ltd., emphasizing the company's position in a highly regulated and competitive industry.